Axsome Therapeutics, Inc.
About Axsome Therapeutics, Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $638.5M
- Net income
- -$183.2M
- Total assets
- $689.8M
- Market cap
- $12.0B
- Operating margin
- -26.1%
- Net margin
- -28.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $638.5M
- Operating expenses
- $805.3M
- Operating income
- -$166.8M
- Income tax
- -$530.0K
- Net income
- -$183.2M
- EPS (basic)
- $-3.68
- EPS (diluted)
- $-3.68
Balance sheet
- Total assets
- $689.8M
- Current assets
- $589.0M
- Total liabilities
- $601.5M
- Current liabilities
- $378.8M
- Shareholders’ equity
- $88.3M
Cash flow
- Operating cash flow
- -$93.4M
- Investing cash flow
- -$480.0K
- Financing cash flow
- $101.5M
- Net cash flow
- $7.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $12.0B
- EPS (diluted)
- $-3.68
- Shares outstanding
- 50.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 19, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $183.2M in FY2025.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Axsome Therapeutics, Inc..
Write a review
News about Axsome Therapeutics, Inc.
News & sentiment via Polygon.io
